Skip to main content

Table 2 Multivariate analysis of overall survival including patients from both Pre-Trastuzumab and Trastuzumab eras

From: Population-based outcomes after brain radiotherapy in patients with brain metastases from breast cancer in the Pre-Trastuzumab and Trastuzumab eras

Characteristics HR (95% CI) p- value
RPA
 1 1 [Reference]  
 2 1.59 (1.12, 2.27) 0.009
 3 3.64 (2.52, 5.27) <0.001
ER status
 Negative 1 [Reference]  
 Positive 0.67 (0.54, 0.84) 0.001
Number of brain lesions
 1 1 [Reference]  
 2-3 1.04 (0.77, 1.41) 0.80
 Multiple 1.36 (1.06, 1.75) 0.017
Craniotomy
 No 1 [Reference]  
 Yes 0.43 (0.31, 0.58) <0.001
Chemotherapy
 No 1 [Reference]  
 Yes 0.59 (0.49, 0.73) <0.001
SRS boost
 No 1 [Reference]  
 Yes 0.40 (0.22, 0.73) 0.003
HER2 (positive vs. negative)
 preT-era 1.02 (0.66, 1.58) 0.92
 T-era 0.49 (0.39, 0.62) <0.001
Hormonal therapy (yes vs. no)
 preT-era 1.09 (0.73, 1.61) 0.68
 T-era 0.62 (0.46, 0.84) 0.002
  1. Abbreviations: RPA = recursive partitioning analysis, ER = estrogen receptor, SRS = stereotactic radiosurgery, HER2 = human epidermal growth factor receptor 2.
Back to article page

Radiation Oncology

ISSN: 1748-717X

Contact us